drugset / Trial / NCT05978713

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

NCT05978713

Phase 1 Completed 11 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.

Timeline

Start
2023-07-31
Primary completion
2024-03-12
Completion
2024-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 5 mg Subcutaneous

Indications

No indication recorded.